Therapeutic importance of subsets of type 2 diabetes?

GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes

“…However, as demonstrated in the UKPDS study, about 80% of adult individuals with recently diagnosed type 2 diabetes and GADA and ICAs progressed to insulin requirements within 6 years, indicating the autoimmune nature of this condition and the progressive beta cell destruction associated with it [15]. At present no treatment modalities have been effective in halting this progression to insulin-requiring diabetes [16]. The approach described here, using alum-formulated GAD65 in an attempt to immunomodulate GADA-positive LADA patients, therefore represents a novel way of interrupting or slowing down the disease progression that leads to beta cell loss and insulin requirement.…”

Induction of long‐term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy

“…The following is a list of criteria that was used to exclude patients from the CSII therapy: (1) proliferative retinopathy, (2) significant renal impairment (more than 2.0 mg/dL of serum creatinine concentrations), (3) coronary heart disease, (4) chronic liver disease, (5) diabetic foot ulceration and gangrene, and (6) pulmonary infections. Since slow onset insulin dependent DM was known to affect only 1 to 2% of Korean type 2 DM patients, it was rejected as a criterion for exclusion or inclusion in the study 16. Over a period of one year (from 1 May 1995 to 30 April 1996), 117 newly hospitalized patients were randomly selected as subjects for this study when either of the numbers, 3 or 6 was generated by rolling a dice.…”